| Effectiveness of oxiracetam therapy in the treatment of cognitive deficiencies secondary to primary degenerative dementia. | |
| | |
MedLine Citation:
|
PMID: 1414555 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The effectiveness of oxiracetam (1600 mg/day) vs placebo was assessed in a group of 96 out-patients suffering from cognitive disorders secondary to primary degenerative dementia. The study, performed in double-blind, lasted 26 weeks and is expected to be continued in open conditions until a whole year of treatment is completed. The assessment of the results obtained at 6 months was carried out following both the methodology based on neuropsychological tests and scales, and the study of the simple reaction time by any of a computerised portable tachystoscope. The patients treated with oxiracetam showed a statistically significant improvement of cognitive function and simple reaction time. No significant variations in the scores of the tests used were observed in the placebo group. The patients themselves appeared in favour of oxiracetam. The drug tolerability proved to be very good for the whole duration of the treatment. The authors believe that oxiracetam favourably acts on the symptoms of senile cerebral deterioration and can improve the capability of information processing, as suggested by the better performances obtained at the reaction time tests. |
| | |
Authors:
|
R Rozzini; O Zanetti; A Bianchetti |
Related Documents
:
|
17183425 - Clinical characteristics and risk factors of delirium in demented and not demented elde... 1634705 - Milacemide: a placebo-controlled study in senile dementia of the alzheimer type. 16354865 - Impact of a disease management program upon caregivers of chronically critically ill pa... 22182405 - Cerebral microdialysis effects of propofol vs midazolam in severe traumatic brain injur... 7042365 - Indoprofen versus indomethacin and placebo. a double-blind three-way cross-over trial i... 15555695 - Suicide attempts: differences between unipolar and bipolar patients and among groups wi... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: Acta neurologica Volume: 14 ISSN: 0001-6276 ISO Abbreviation: Acta Neurol (Napoli) Publication Date: 1992 Apr |
Date Detail:
|
Created Date: 1992-11-03 Completed Date: 1992-11-03 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 0421100 Medline TA: Acta Neurol (Napoli) Country: ITALY |
Other Details:
|
Languages: eng Pagination: 117-26 Citation Subset: IM |
Affiliation:
|
Department of General Medicine, Ospedale S. Opsola, Brescia. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Aged, 80 and over Cognition Disorders / drug therapy*, etiology Dementia / complications* Double-Blind Method Female Humans Male Neuropsychological Tests Psychotropic Drugs / therapeutic use* Pyrrolidines / therapeutic use* Reaction Time |
| Chemical | |
Reg. No./Substance:
|
0/Psychotropic Drugs; 0/Pyrrolidines; 62613-82-5/oxiracetam |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Hemianopic ataxic hemiparesis. A case report.
Next Document: Acute encephalopathy following lumbar myelography with iohexol.